EUVIMEDTutustu EUVIMEDiin
Open access · CC BY-NC-ND 4.0

Extracorporeal Photopheresis for Chronic Graft‐Versus‐Host Disease According to 2014 NIH Consensus Criteria

Yitzhar Goretsky iD, Noa Holtzman, Sunwoo Han, Isildinha M Reis, Vera Suzuki, Pepita Jean, Karla Mones, Meilin Diaz-Paez, Cara Benjamin, Amer Beitinjaneh, Mark Goodman, Antonio Jimenez Jimenez and 7 more

Journal of Clinical Apheresis · 2025

DOI: 10.1002/jca.70075 ↗

At a glance

Journal article in Journal of Clinical Apheresis, 2025. Written by Yitzhar Goretsky and 18 co-authors. Institution: University of Miami Miller School of Medicine, Miami, Florida, USA. Major MEDLINE topics: Bronchiolitis Obliterans Syndrome, Photopheresis. 47 references. The full text is freely available (open access, CC BY-NC-ND 4.0). Funded by: NCI NIH HHS, National Cancer Institute.

TiivistelmäSubjectsBibliografiset tiedotCiteRelated studies

Abstract (original language)

Chronic graft‐versus‐host disease (cGVHD) remains a major cause of morbidity and mortality following allogeneic hematopoietic stem cell transplantation. Many cGVHD patients require prolonged systemic immunosuppression with corticosteroids, which carry significant adverse effects, and alternative therapies are often required. Extracorporeal photopheresis (ECP) has historically shown promise as a cGVHD treatment, but recent efficacy data have been limited and inconsistent. To evaluate the efficacy of ECP as a treatment for cGVHD patients according to the 2014 NIH Consensus Criteria. We retrospectively analyzed 53 patients treated with ECP for cGVHD at our center from 2010 to 2024. ORR was 51%, with 3 CRs (5.7%) and 24 PRs (45.3%). Highest organ‐specific responses were seen in the gastrointestinal tract (70%) and liver (69.2%), and lowest in joints/fascia (15.4%) and lung (21.4%). A total of 23 (43.4%) patients experienced at least one treatment‐related complication (TRC), with a median time to first TRC of 29.3 weeks (IQR = 7.4–55.2). The estimated 1‐ and 3‐year OS was 79.2% (95% CI = 65.7%–87.9%) and 70.1% (95% CI = 55.0%–80.9%), respectively. The estimated 1‐ and 3‐year FFS was 75.5% (95% CI = 61.5%–84.9%) and 43.1% (95% CI = 28.6%–56.9%), respectively. Of the 37 patients who were on corticosteroids at the start of ECP, 22 (59.5%) were able to decrease their daily dose by ≥ 50% by the time of ECP discontinuation. Multivariable analyses revealed that patients on tacrolimus and other non‐steroid immunosuppressive treatments (ISTs) had better outcomes in clinical benefit, steroid‐sparing, overall survival, and failure‐free survival. ECP was a safe and effective treatment for cGVHD in our population and showed promising efficacy when used in combination with tacrolimus or other ISTs.

Subjects

MeSH terms (MEDLINE)

Bronchiolitis Obliterans SyndromePhotopheresisHumansHematopoietic Stem Cell TransplantationRetrospective StudiesSurvival RateAdrenal Cortex HormonesImmunosuppressive AgentsTacrolimusTreatment OutcomeMaleFemaleYoung AdultAdultMiddle AgedAged

Author keywords

extracorporeal photopheresisgraft‐versus‐host diseasehematopoietic stem cell transplantationsteroids

Substances

Adrenal Cortex HormonesImmunosuppressive AgentsTacrolimus

Authors and institutions

  • University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Division of Transplantation and Cellular Therapy, Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Sylvester Comprehensive Cancer Center, Miami, Florida, USA.
  • Biostatistics and Bioinformatics Shared Resource, Sylvester Comprehensive Cancer Center, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Department of Public Health Sciences, University of Miami Miller School of Medicine, Miami, Florida, USA.
  • Department of Pathology and Laboratory Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA.

ORCID profiles: Yitzhar Goretsky, Trent P Wang

Funding

  • NCI NIH HHS
  • National Cancer Institute

Cite

APA

Goretsky, Y., Holtzman, N., Han, S., Reis, I. M., Suzuki, V., Jean, P., Mones, K., Diaz-Paez, M., Benjamin, C., Beitinjaneh, A., Goodman, M., Jimenez, A. J., Lekakis, L., Pereira, D., Spiegel, J., Wu, Y., Green, D. J., Komanduri, K. V., & Wang, T. P. (2025). Extracorporeal Photopheresis for Chronic Graft‐Versus‐Host Disease According to 2014 NIH Consensus Criteria. Journal of Clinical Apheresis. https://doi.org/10.1002/jca.70075

Vancouver

Goretsky Y, Holtzman N, Han S, Reis IM, Suzuki V, Jean P, et al. Extracorporeal Photopheresis for Chronic Graft‐Versus‐Host Disease According to 2014 NIH Consensus Criteria. Journal of Clinical Apheresis. 2025. doi:10.1002/jca.70075

BibTeX
@article{Goretsky2025,
  author = {Goretsky, Yitzhar and Holtzman, Noa and Han, Sunwoo and Reis, Isildinha M and Suzuki, Vera and Jean, Pepita and Mones, Karla and Diaz-Paez, Meilin and Benjamin, Cara and Beitinjaneh, Amer and Goodman, Mark and Jimenez, Antonio Jimenez and Lekakis, Lazaros and Pereira, Denise and Spiegel, Jay and Wu, Yanyun and Green, Damian J and Komanduri, Krishna V and Wang, Trent P},
  title = {Extracorporeal Photopheresis for Chronic Graft‐Versus‐Host Disease According to 2014 NIH Consensus Criteria},
  journal = {Journal of Clinical Apheresis},
  year = {2025},
  doi = {10.1002/jca.70075}
}
Start for free →